Novartis Acquires Mutant-Selective PI3Kα Inhibi...

By HEOR Staff Writer

March 23, 2026

Novartis has agreed to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor from Sy...
Semaglutide India Partnership: Enhancing Access to Diabetes Treatment
Wegovy HD Approval: A Game Changer in Obesity Treatment and Weight Loss Efficacy
Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal...
Accelerating Patient Access: MHRA NICE Alignment Initiative
Long-Term HPV Vaccine Effectiveness: Sustained Protection Against Cervical Di...
TAVI Reimbursement Expansion for Low- and Intermediate-Risk Patients: A New E...
PRIME Scheme Evaluation: Insights from Enhanced Development Tools Pilot
EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy
Europe Life Sciences Competitiveness: Addressing Decline and Unlocking Potential
Bridging Analyses: The Role of Cost Per Event Avoided in Evaluating GLP-1 Ago...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis